Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12305226 | 0.90 | TLR7 (0.47) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL822730 | 0.85 | TLR7 (0.53) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2058782 | 0.84 | YTHDC1 (0.55) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12305228 | 0.84 | TLR7 (0.45) | TLR7 | |
| SCHEMBL7206653 | 0.84 | TLR7 (0.51) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12305231 | 0.83 | TLR7 (0.52) | TLR7NUDT1 | |
| SCHEMBL16481581 | 0.80 | TLR7 (0.52) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17154082 | 0.80 | TLR7 (0.52) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL509407 | 0.79 | TLR7 (0.64) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3957806 | 0.79 | AXL (0.51) | TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611268-B2 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611268-B2 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150239888-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239888-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| EP-2170888-B1 | PURINE DERIVATIVES AND THEIR USE AS MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8993755-B2 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2015-03-31 | — | — | US | disclosed |
| US-8993755-B2 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2015-03-31 | — | — | US | disclosed |
| US-20140135492-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. | 2014-05-15 | — | — | US | disclosed |
| US-20140135492-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. | 2014-05-15 | — | — | US | disclosed |
| US-20120244121-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120244121-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20110236348-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110236348-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-7968544-B2 | Agonists; Treatment of Hepatitis C virus; purine derivatives | GILEAD SCIENCES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968544-B2 | Agonists; Treatment of Hepatitis C virus; purine derivatives | GILEAD SCIENCES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090047249-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090047249-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135492-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | TLR7 1/4885PDE4A 1427/4885PDE4B 1548/4885 |
| US-20090047249-A1 | Modulators of toll-like receptor 7 | TLR7, TLR6, TLR3 | TLR7 1/4885PDE4A 1386/4885PDE4B 1552/4885 |
| US-20110236348-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | TLR7 1/4885PDE4A 1018/4885PDE4B 1212/4885 |
| US-20150239888-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | TLR7 1/4885PDE4A 1427/4885PDE4B 1548/4885 |
| US-20120244121-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | TLR7 1/4885PDE4A 1018/4885PDE4B 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.